Home › Companies › Nurix Therapeutics, Inc. › 2025-2026

Nurix Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Nurix Therapeutics, Inc.’s Form 8-K, filed May 15, 2026 (Item 5.07 on EDGAR). Page generated October 18, 2026.

5Ballot items
215Asset managers
1,232Fund votes
May 15, 2026Meeting date

Results at a glance

Meeting of May 15, 2026: 5 items on Nurix Therapeutics, Inc.’s Form 8-K, filed May 15, 2026: 3 elected · 2 approved.

Material dissent

Elect Director: Paul M. Silva 74% of votes cast Elected Director under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Nurix Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Nurix Therapeutics, Inc.

These tallies are Nurix Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 15, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Nurix Therapeutics, Inc. — official shareholder meeting results, meeting held May 15, 2026
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Arthur T. Sands, M.D., Ph.D.	63,592,948	--	--	16,334,570	3,819,495	80%	Elected	—
Elect Director: Roger Dansey, M.D.	79,607,489	--	--	320,029	3,819,495	99.5%	Elected	—
Elect Director: Paul M. Silva	59,298,612	--	--	20,628,906	3,819,495	74%	Elected	—
2. Ratification of Appointment of Independent Registered Public Accounting Firm	83,555,977	166,391	24,645	--	--	99.8%	Approved	—
3. Approval, on a Non-binding Advisory Basis, of the Compensation of the Company's Named Executive Officers	72,458,920	6,895,394	573,204	--	3,819,495	91%	Approved	—

Source: Nurix Therapeutics, Inc., Form 8-K, filed with the SEC on May 15, 2026 — read the filing on EDGAR.

How asset managers voted at the Nurix Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 215 asset managers that disclosed a Nurix Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Arthur T. Sands, M.D., Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

80% Majority: yes · of votes cast

FOR 80%WITHHELD

FOR: 63,592,948WITHHELD: 16,334,570

Details: description as filed, official tally, votes by 57 asset managers

Description as filed by funds: Election of Class III Directors: Arthur T. Sands, M.D., Ph.D.

Nurix Therapeutics, Inc.’s own tally for this item (“Elect Director: Arthur T. Sands, M.D., Ph.D.”): 63,592,948 for, 16,334,570 withheld, per its Form 8-K filed May 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the three nominees for director was elected to serve until the Company's 2029 annual meeting of stockholders and until his successor has been elected and qualified, or until his earlier resignation or removal.”
Support: 80% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 23,121,907 for, 4,366,423 withheld, 141,473 abstained.

FORWITHHOLD

FOR: 23,121,907ABSTAIN: 141,473WITHHOLD: 4,366,423

Largest asset managers voting on “Election of Class III Directors: Arthur T. Sands, M.D., Ph.D.” at Nurix Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Fidelity	2,167,834	0	3,564,112	Mixed
Vanguard	5,404,439	7,800	0	For
BlackRock	4,833,259	0	0	For
T. Rowe Price	2,265,179	0	0	For
ARK ETF Trust	1,632,038	0	0	For
State Street	1,528,323	0	3,868	For
MUTUAL FUND SERIES TRUST	1,297,893	0	25,571	For
Charles Schwab	922,609	0	0	For
Capital Group	893,327	0	0	For
TIAA	744,345	0	0	For
Dimensional	0	0	258,949	Withhold
Equitable	187,038	0	63,470	Mixed
Goldman Sachs	211,153	0	0	For
Invesco	170,368	0	0	For
QUANTITATIVE MASTER SERIES LLC	164,620	0	0	For
Brighthouse	65,163	0	32,631	Mixed
CARILLON SERIES TRUST	0	88,158	0	Abstain
Nationwide	50,533	0	31,966	Mixed
American Century	0	0	77,991	Withhold
Northern Trust	70,735	0	0	For
Lincoln Financial	66,600	0	1,279	For
Global X	67,374	0	0	For
John Hancock	30,577	29,298	0	Mixed
AIG/SunAmerica	0	0	58,276	Withhold
Columbia Threadneedle	56,135	0	0	For

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

2. Elect Director: Paul M. Silva

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD

FOR: 59,298,612WITHHELD: 20,628,906

Details: description as filed, official tally, votes by 57 asset managers

Description as filed by funds: Election of Class III Directors: Paul M. Silva

Nurix Therapeutics, Inc.’s own tally for this item (“Elect Director: Paul M. Silva”): 59,298,612 for, 20,628,906 withheld, per its Form 8-K filed May 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the three nominees for director was elected to serve until the Company's 2029 annual meeting of stockholders and until his successor has been elected and qualified, or until his earlier resignation or removal.”
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 21,391,262 for, 6,097,061 withheld, 141,479 abstained.

FORWITHHOLD

FOR: 21,391,262ABSTAIN: 141,479WITHHOLD: 6,097,061

Largest asset managers voting on “Election of Class III Directors: Paul M. Silva” at Nurix Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Fidelity	2,167,834	0	3,564,112	Mixed
Vanguard	5,400,751	7,806	3,682	For
BlackRock	4,833,259	0	0	For
T. Rowe Price	2,265,179	0	0	For
ARK ETF Trust	1,632,038	0	0	For
State Street	1,030	0	1,531,161	Withhold
MUTUAL FUND SERIES TRUST	1,297,893	0	25,571	For
Charles Schwab	922,609	0	0	For
Capital Group	893,327	0	0	For
TIAA	744,345	0	0	For
Dimensional	0	0	258,949	Withhold
Equitable	187,038	0	63,470	Mixed
Goldman Sachs	211,153	0	0	For
Invesco	170,368	0	0	For
QUANTITATIVE MASTER SERIES LLC	164,620	0	0	For
Brighthouse	65,163	0	32,631	Mixed
CARILLON SERIES TRUST	0	88,158	0	Abstain
Nationwide	50,533	0	31,966	Mixed
American Century	0	0	77,991	Withhold
Northern Trust	0	0	70,735	Withhold
Lincoln Financial	0	0	67,879	Withhold
Global X	46,204	0	21,170	Mixed
John Hancock	30,577	29,298	0	Mixed
AIG/SunAmerica	0	0	58,276	Withhold
Columbia Threadneedle	56,135	0	0	For

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

3. Elect Director: Roger Dansey, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

99.5% Majority: yes · of votes cast

FOR 99.5%

FOR: 79,607,489WITHHELD: 320,029

Details: description as filed, official tally, votes by 57 asset managers

Description as filed by funds: Election of Class III Directors: Roger Dansey, M.D.

Nurix Therapeutics, Inc.’s own tally for this item (“Elect Director: Roger Dansey, M.D.”): 79,607,489 for, 320,029 withheld, per its Form 8-K filed May 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the three nominees for director was elected to serve until the Company's 2029 annual meeting of stockholders and until his successor has been elected and qualified, or until his earlier resignation or removal.”
Support: 99.5% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 27,629,803 for.

FOR

FOR: 27,629,803

Largest asset managers voting on “Election of Class III Directors: Roger Dansey, M.D.” at Nurix Therapeutics, Inc., 2025-2026
Asset manager	For	Vote
Fidelity	5,731,946	For
Vanguard	5,412,239	For
BlackRock	4,833,259	For
T. Rowe Price	2,265,179	For
ARK ETF Trust	1,632,038	For
State Street	1,532,191	For
MUTUAL FUND SERIES TRUST	1,323,464	For
Charles Schwab	922,609	For
Capital Group	893,327	For
TIAA	744,345	For
Dimensional	258,949	For
Equitable	250,508	For
Goldman Sachs	211,153	For
Invesco	170,368	For
QUANTITATIVE MASTER SERIES LLC	164,620	For
Brighthouse	97,794	For
CARILLON SERIES TRUST	88,158	For
Nationwide	82,499	For
American Century	77,991	For
Northern Trust	70,735	For
Lincoln Financial	67,879	For
Global X	67,374	For
John Hancock	59,875	For
AIG/SunAmerica	58,276	For
Columbia Threadneedle	56,135	For

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

4. 3. Approval, on a Non-binding Advisory Basis, of the Compensation of the Company's Named Executive Officers

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

91% Approved · of votes cast

FOR 91%

FOR: 72,458,920AGAINST: 6,895,394

Details: description as filed, official tally, votes by 215 asset managers

Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.

Nurix Therapeutics, Inc.’s own tally for this item (“3. Approval, on a Non-binding Advisory Basis, of the Compensation of the Company's Named Executive Officers”): 72,458,920 for, 6,895,394 against — passed, per its Form 8-K filed May 15, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3. Approval, on a Non-binding Advisory Basis, of the Compensation of the Company's Named Executive Officers”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 56 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as dis” at Nurix Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Fidelity	2,167,834	3,564,112	0	Mixed
Vanguard	5,412,225	12	1	For
BlackRock	4,833,259	0	0	For
T. Rowe Price	2,265,179	0	0	For
ARK ETF Trust	1,632,038	0	0	For
State Street	1,532,131	60	0	For
MUTUAL FUND SERIES TRUST	1,323,464	0	0	For
Charles Schwab	922,609	0	0	For
Capital Group	0	893,327	0	Against
TIAA	744,345	0	0	For
Dimensional	258,949	0	0	For
Equitable	250,508	0	0	For
Goldman Sachs	211,153	0	0	For
Invesco	0	170,368	0	Against
QUANTITATIVE MASTER SERIES LLC	164,620	0	0	For
Brighthouse	97,794	0	0	For
CARILLON SERIES TRUST	88,158	0	0	For
Nationwide	82,499	0	0	For
American Century	0	77,991	0	Against
Northern Trust	70,735	0	0	For
Lincoln Financial	67,879	0	0	For
Global X	67,374	0	0	For
John Hancock	59,875	0	0	For
AIG/SunAmerica	58,276	0	0	For
Columbia Threadneedle	56,135	0	0	For

Fund voting reports, all 56 managers: 22,923,931 for, 4,705,870 against, 1 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 174 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as dis” at Nurix Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Redmile Group, LLC	7,902,808	0	0	For
Deep Track Capital, LP	5,198,303	0	0	For
Fidelity	0	4,860,200	0	Against
BAKER BROS. ADVISORS LP	4,597,916	0	0	For
State Street	3,448,820	18,640	0	For
BlackRock	3,440,394	0	0	For
T. Rowe Price	3,205,718	0	0	For
GENERAL ATLANTIC, L.P.	0	0	3,032,185	Abstain
Vestal Point Capital, LP	3,023,716	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	2,480,162	0	0	For
PICTET ASSET MANAGEMENT SA	2,470,194	0	0	For
Rubric Capital Management LP	2,447,623	0	0	For
PERCEPTIVE ADVISORS LLC	2,307,270	0	0	For
Commodore Capital LP	1,662,871	0	0	For
Trails Edge Capital Partners, LP	1,412,367	0	0	For
Amova Asset Management Co., Ltd.	1,186,447	0	0	For
Charles Schwab	922,942	0	0	For
Capital Group	0	893,327	0	Against
Nuveen	780,321	0	0	For
Vanguard	721,073	0	0	For
Northern Trust	659,792	7,040	0	For
Affinity Asset Advisors, LLC	628,444	0	0	For
Candriam S.C.A.	0	0	534,259	Abstain
BRAIDWELL LP	524,296	0	0	For
Handelsbanken Fonder AB	492,298	0	0	For

Institutional-manager reports, all 174 managers: 56,682,464 for, 6,454,081 against, 473,485 withheld, 3,567,019 abstained, 352 not voted. Showing the 25 largest; see all in the interactive database.

5. 2. Ratification of Appointment of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.8% Approved · of votes cast

FOR 99.8%

FOR: 83,555,977AGAINST: 166,391

Details: description as filed, official tally, votes by 57 asset managers

Description as filed by funds: Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending November 30, 2026.

Nurix Therapeutics, Inc.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm”): 83,555,977 for, 166,391 against — passed, per its Form 8-K filed May 15, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending November 30, 2026.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 27,629,743 for, 60 against.

FOR

FOR: 27,629,743AGAINST: 60

Largest asset managers voting on “Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public a” at Nurix Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Fidelity	5,731,946	0	For
Vanguard	5,412,239	0	For
BlackRock	4,833,259	0	For
T. Rowe Price	2,265,179	0	For
ARK ETF Trust	1,632,038	0	For
State Street	1,532,131	60	For
MUTUAL FUND SERIES TRUST	1,323,464	0	For
Charles Schwab	922,609	0	For
Capital Group	893,327	0	For
TIAA	744,345	0	For
Dimensional	258,949	0	For
Equitable	250,508	0	For
Goldman Sachs	211,153	0	For
Invesco	170,368	0	For
QUANTITATIVE MASTER SERIES LLC	164,620	0	For
Brighthouse	97,794	0	For
CARILLON SERIES TRUST	88,158	0	For
Nationwide	82,499	0	For
American Century	77,991	0	For
Northern Trust	70,735	0	For
Lincoln Financial	67,879	0	For
Global X	67,374	0	For
John Hancock	59,875	0	For
AIG/SunAmerica	58,276	0	For
Columbia Threadneedle	56,135	0	For

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

Largest Nurix Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 103,405,813 shares outstanding at the time of that meeting.

Fund voting reports: top Nurix Therapeutics, Inc. shareholders by shares voted on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive…”, 2025-2026
#	Asset manager	% of shares outstanding
1	Fidelity	5.54%
2	Vanguard	5.23%
3	BlackRock	4.67%
4	T. Rowe Price	2.19%
5	ARK ETF Trust	1.58%
6	State Street	1.48%
7	MUTUAL FUND SERIES TRUST	1.28%
8	Charles Schwab	0.89%
9	Capital Group	0.86%
10	TIAA	0.72%

Institutional-manager reports: top Nurix Therapeutics, Inc. shareholders by shares voted on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive…”, 2025-2026
#	Asset manager	% of shares outstanding
1	Redmile Group, LLC	7.64%
2	Deep Track Capital, LP	5.03%
3	Fidelity	4.70%
4	BAKER BROS. ADVISORS LP	4.45%
5	State Street	3.35%
6	BlackRock	3.33%
7	T. Rowe Price	3.10%
8	GENERAL ATLANTIC, L.P.	2.93%
9	Vestal Point Capital, LP	2.92%
10	GEODE CAPITAL MANAGEMENT, LLC	2.40%

Reported Nurix Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

Nurix Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
BlackRock	8.63%	13F
Redmile Group, LLC	8.49%	13G
Vestal Point Capital, LP	7.78%	13G
Deep Track Capital, LP	7.48%	13G
Baker Bros. Advisors LP	7.28%	13G
Rubric Capital Management LP	6.99%	13G
Vanguard Group	5.75%	13F
FMR (Fidelity)	5.36%	13F
State Street	4.97%	13F
Morgan Stanley	4.72%	13F

Percentages above are of 103,405,813 shares outstanding, as reported by Nurix Therapeutics, Inc. on its Form 10-Q dated April 1, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Nurix Therapeutics, Inc.’s 10-Q dated April 1, 2026. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.

At Nurix Therapeutics, Inc.'s shareholder meeting held May 15, 2026, in the 2025-2026 proxy season, 215 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,232 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of the Company's named executive… — Nurix Therapeutics, Inc.'s filing reports the proposal as approved, with 91% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Nurix Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 15, 2026.

Nurix Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Download data (CSV): ballot items · votes by manager · column guide.